# Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)

> **NCT02615145** · — · COMPLETED · sponsor: **AbbVie** · enrollment: 472 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02615145
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-03
- **Primary completion:** 2018-03-26
- **Final completion:** 2018-03-26
- **Target enrollment:** 472 (ACTUAL)
- **Last updated:** 2019-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02615145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02615145, "Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02615145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*